Abstract
The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12% before screening to 0% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2% to 0.73%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Black People / statistics & numerical data
-
Dideoxynucleosides / adverse effects*
-
Dideoxynucleosides / therapeutic use
-
Female
-
France / epidemiology
-
France / ethnology
-
Genetic Testing*
-
HIV
-
HIV Infections / drug therapy
-
HIV Infections / immunology
-
HLA-B Antigens / genetics*
-
Humans
-
Hypersensitivity / genetics
-
Hypersensitivity / prevention & control*
-
Incidence
-
Male
-
Middle Aged
-
Polymerase Chain Reaction / economics
-
Polymerase Chain Reaction / methods
-
Predictive Value of Tests
-
Prospective Studies
-
Retrospective Studies
-
Sensitivity and Specificity
-
Suburban Population
-
Urban Population
-
White People / statistics & numerical data
Substances
-
Anti-HIV Agents
-
Dideoxynucleosides
-
HLA-B Antigens
-
HLA-B*57:01 antigen
-
abacavir